|
Ebalzotan (NAE-086) is a selective 5-HT1A receptor agonist. It was under development as an antidepressant and anxiolytic agent but produced undesirable side effects in phase I clinical trials and was subsequently discontinued. == See also == * Robalzotan 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Ebalzotan」の詳細全文を読む スポンサード リンク
|